viTToria Biotherapeutics and Exyn Technologies, both startups co-founded by Penn faculty, won recent awards from the Philadelphia Alliance for Capital and Technologies.
Verismo Therapeutics Activates its STAR-101 Clinical Trial to Evaluate Investigational Drug SynKIR-110
Penn spinout Verismo Therapeutics, which focuses on CAR T-cell therapy for solid tumors, has activated its STAR-101 Phase 1 clinical trial at Penn.
In an interview about her long-term vision for the university with the Philadelphia Business Journal, Penn President Liz Magill mentions Penn’s breakthroughs in cell and gene therapy.
Penn spinout REGENXBIO received FDA Fast Track designation for its novel gene therapy candidate RGX-202, a potential one-time AAV Therapeutic for the treatment of Duchenne muscular dystrophy.
Penn was highlighted in The Daily Pennsylvanian for ranking first in annual licensing income among 153 research institutions.
This in-depth interview with Swartley provides a comprehensive history about technology transfer at Penn as well as the establishment and current success of PCI.
Penn officially ranked number one in terms of licensing income in the latest Association of University Technology Managers (AUTM) annual survey, which included 153 reporting institutions.
Ellie Weinstein, Pennovation Accelerator alumni, developed the Cocoa Press to 3D print chocolate.
The CEO Council for Growth recently highlighted PCI's annual review and JP Morgan Conference event in its newsletter.
PCI supported Penn spinouts Interius BioTherapeutics, Verismo Therapeutics, viTToria biotherapeutics, Exyn Technologies, and Avisi Technologies are all nominated for awards.